Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus

Philippe Metz, Eva Dazert, Johanna Mazur, Michael FRESE, Lars Kaderali, Volker Lohmann, Ralf Bartenschlager

Research output: Contribution to conference (non-published works)Abstract

Abstract

Persistent infection with the hepatitis C virus (HCV) may lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Current therapy relies on the antiviral activity of interferon-alpha (IFN-alpha) that is given alone or in combination with ribavirin. However, treatment outcomes for the most prevalent genotypes are still not optimal, and side effects limit therapy success. Moreover, antiviral T cell responses targeting HCV appear to be mediated primarily by IFN-gamma, but the effectors responsible for replication inhibition are not known. IFNs induce the expression of a multitude of IFN-stimulated genes (ISGs), but for the majority, little is known about their anti-HCV potential and mode-of-action. Here we report a novel RNAi-based screening assay designed to identify ISGs contributing to the inhibition of HCV replication. The assay is based on the restoration of viral replication in the presence of IFNs by knockdown of ISGs. In this way we identified 6 ISGs with previously unreported antiviral activity. One of them was specific for IFN-alpha, one for IFN-gamma and 4 were induced by either cytokine, demonstrating a substantial overlap of the respective signalling and effector pathways. Combinatorial knockdowns of these ISGs after IFN treatment suggest additive effects. In conclusion, our study identifies several ISGs contributing to the block of HCV replication by type 1 and type 2 IFN and they suggest that inhibition is conferred by the combined action of several ISGs.
Original languageEnglish
Pages20-20
Number of pages1
Publication statusPublished - Mar 2011
EventThe International Liver Congress 2011: 46th Annual meeting of the European Association for the Study of the Liver - Berlin, Berlin, Germany
Duration: 30 Mar 20113 Apr 2011

Conference

ConferenceThe International Liver Congress 2011
Abbreviated titleEASL 2011
CountryGermany
CityBerlin
Period30/03/113/04/11

Fingerprint

Hepacivirus
Interferons
Antiviral Agents
Genes
Virus Replication
Interferon-alpha
Ribavirin
Chronic Hepatitis
RNA Interference
Liver Cirrhosis
Action Potentials
Hepatocellular Carcinoma
Genotype
Cytokines
T-Lymphocytes
Therapeutics
Infection

Cite this

Metz, P., Dazert, E., Mazur, J., FRESE, M., Kaderali, L., Lohmann, V., & Bartenschlager, R. (2011). Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus. 20-20. Abstract from The International Liver Congress 2011, Berlin, Germany.
Metz, Philippe ; Dazert, Eva ; Mazur, Johanna ; FRESE, Michael ; Kaderali, Lars ; Lohmann, Volker ; Bartenschlager, Ralf. / Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus. Abstract from The International Liver Congress 2011, Berlin, Germany.1 p.
@conference{3aff0d4fa2184e98844322ec0f05eeb8,
title = "Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus",
abstract = "Persistent infection with the hepatitis C virus (HCV) may lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Current therapy relies on the antiviral activity of interferon-alpha (IFN-alpha) that is given alone or in combination with ribavirin. However, treatment outcomes for the most prevalent genotypes are still not optimal, and side effects limit therapy success. Moreover, antiviral T cell responses targeting HCV appear to be mediated primarily by IFN-gamma, but the effectors responsible for replication inhibition are not known. IFNs induce the expression of a multitude of IFN-stimulated genes (ISGs), but for the majority, little is known about their anti-HCV potential and mode-of-action. Here we report a novel RNAi-based screening assay designed to identify ISGs contributing to the inhibition of HCV replication. The assay is based on the restoration of viral replication in the presence of IFNs by knockdown of ISGs. In this way we identified 6 ISGs with previously unreported antiviral activity. One of them was specific for IFN-alpha, one for IFN-gamma and 4 were induced by either cytokine, demonstrating a substantial overlap of the respective signalling and effector pathways. Combinatorial knockdowns of these ISGs after IFN treatment suggest additive effects. In conclusion, our study identifies several ISGs contributing to the block of HCV replication by type 1 and type 2 IFN and they suggest that inhibition is conferred by the combined action of several ISGs.",
keywords = "hepatitis C virus, Interferon",
author = "Philippe Metz and Eva Dazert and Johanna Mazur and Michael FRESE and Lars Kaderali and Volker Lohmann and Ralf Bartenschlager",
year = "2011",
month = "3",
language = "English",
pages = "20--20",
note = "The International Liver Congress 2011 : 46th Annual meeting of the European Association for the Study of the Liver, EASL 2011 ; Conference date: 30-03-2011 Through 03-04-2011",

}

Metz, P, Dazert, E, Mazur, J, FRESE, M, Kaderali, L, Lohmann, V & Bartenschlager, R 2011, 'Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus' The International Liver Congress 2011, Berlin, Germany, 30/03/11 - 3/04/11, pp. 20-20.

Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus. / Metz, Philippe; Dazert, Eva; Mazur, Johanna; FRESE, Michael; Kaderali, Lars; Lohmann, Volker; Bartenschlager, Ralf.

2011. 20-20 Abstract from The International Liver Congress 2011, Berlin, Germany.

Research output: Contribution to conference (non-published works)Abstract

TY - CONF

T1 - Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus

AU - Metz, Philippe

AU - Dazert, Eva

AU - Mazur, Johanna

AU - FRESE, Michael

AU - Kaderali, Lars

AU - Lohmann, Volker

AU - Bartenschlager, Ralf

PY - 2011/3

Y1 - 2011/3

N2 - Persistent infection with the hepatitis C virus (HCV) may lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Current therapy relies on the antiviral activity of interferon-alpha (IFN-alpha) that is given alone or in combination with ribavirin. However, treatment outcomes for the most prevalent genotypes are still not optimal, and side effects limit therapy success. Moreover, antiviral T cell responses targeting HCV appear to be mediated primarily by IFN-gamma, but the effectors responsible for replication inhibition are not known. IFNs induce the expression of a multitude of IFN-stimulated genes (ISGs), but for the majority, little is known about their anti-HCV potential and mode-of-action. Here we report a novel RNAi-based screening assay designed to identify ISGs contributing to the inhibition of HCV replication. The assay is based on the restoration of viral replication in the presence of IFNs by knockdown of ISGs. In this way we identified 6 ISGs with previously unreported antiviral activity. One of them was specific for IFN-alpha, one for IFN-gamma and 4 were induced by either cytokine, demonstrating a substantial overlap of the respective signalling and effector pathways. Combinatorial knockdowns of these ISGs after IFN treatment suggest additive effects. In conclusion, our study identifies several ISGs contributing to the block of HCV replication by type 1 and type 2 IFN and they suggest that inhibition is conferred by the combined action of several ISGs.

AB - Persistent infection with the hepatitis C virus (HCV) may lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Current therapy relies on the antiviral activity of interferon-alpha (IFN-alpha) that is given alone or in combination with ribavirin. However, treatment outcomes for the most prevalent genotypes are still not optimal, and side effects limit therapy success. Moreover, antiviral T cell responses targeting HCV appear to be mediated primarily by IFN-gamma, but the effectors responsible for replication inhibition are not known. IFNs induce the expression of a multitude of IFN-stimulated genes (ISGs), but for the majority, little is known about their anti-HCV potential and mode-of-action. Here we report a novel RNAi-based screening assay designed to identify ISGs contributing to the inhibition of HCV replication. The assay is based on the restoration of viral replication in the presence of IFNs by knockdown of ISGs. In this way we identified 6 ISGs with previously unreported antiviral activity. One of them was specific for IFN-alpha, one for IFN-gamma and 4 were induced by either cytokine, demonstrating a substantial overlap of the respective signalling and effector pathways. Combinatorial knockdowns of these ISGs after IFN treatment suggest additive effects. In conclusion, our study identifies several ISGs contributing to the block of HCV replication by type 1 and type 2 IFN and they suggest that inhibition is conferred by the combined action of several ISGs.

KW - hepatitis C virus

KW - Interferon

M3 - Abstract

SP - 20

EP - 20

ER -

Metz P, Dazert E, Mazur J, FRESE M, Kaderali L, Lohmann V et al. Identification of effectors of the Interferon-induced Antiviral response against Hepatitis C Virus. 2011. Abstract from The International Liver Congress 2011, Berlin, Germany.